Hannah Clarke

"Our new study is the first post-market analysis to see how doctors are using this drug in routine practice and what their patient outcomes are,” said Soloman Woldu, MD.

In response to the findings, The American Cancer Society is launching IMPACT, an initiative aimed at reducing prostate cancer mortality.

MRI-guided SBRT reduced both acute toxicity effects and decrements in quality-of-life measures when compared with CT-guided SBRT, according to findings published in JAMA Oncology.

The environmental footprint of prostate MRI and prostate biopsy is similar to a round-trip flight from London to Paris, according to the authors.

"Even though most of the end points had been negative and found no benefit, I think there are a couple of findings that we've learned in 2022 that surprised me," says Mark A. Moyad, MD, MPH.

“Improved quality of life is the key benefit for our BPH patients," says Scott Barkin, DO.

The acceptance allows investigators to proceed with the phase 1/2a study of the intraoperative immunotherapy SURGERx with resiquimod (STM-416).

The new payment rate goes into effect January 2023 and will expand access to care for Medicare beneficiaries.

“Each unit of blood that you got during surgery was associated with about 7% higher odds of a VTE within 90 days,” says Timothy D. Lyon, MD, FACS.

Here is some of the top content on genomic testing from the past year.

"I think NAI plus BCG will be a game-changer in the community, probably more than it would be in academic medical settings," says Karim Chamie, MD.

“The number of views, viewer engagement, and the length of the video didn't have an impact on the score at all when we did our analysis,” says Daniel Bockelman.

As the year comes to a close, we revisit some of this year’s top content on malpractice in urology.

As the year comes to a close, we revisit some of this year’s top content on urologic stones.

As the year comes to a close, we revisit some of this year’s top content on next-generation imaging.

Dr. Butler discusses 2022 milestones from her practice in gender-affirming care and looks ahead to what might be on the horizon for the field in the coming year.

As the year comes to a close, we revisit some of this year’s top content on coding and reimbursement for urologic procedures.

As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.

Thomas Chi, MD, discusses 2022 milestones in stone disease and looks ahead to what might be on the horizon for the field in the coming year.

Investigators found that mitigation methods such as adding a physical barrier or increasing distance could lessen the harmful effects.

As the year comes to a close, we revisit some of this year’s top content on diversity, equity, and inclusion.

As the year comes to a close, we revisit some of this year’s top content on bladder cancer.

As the year comes to a close, we revisit some of this year’s top content on kidney cancer.

"The previous group who had looked at this saw a 15% adherence to the AUA guidelines up to 2013. We're doing better, but not much better," says Megan Prunty, MD.

“Even though we set some priority areas, we also allow practicing urologists to make suggestions for things that they want to know about,” says Amanda North, MD.

Dr. Van Kuiken discusses 2022 milestones in FPMRS and looks ahead to what might be on the horizon for the field in the coming year.

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.

“The bottom line is that [gender parity] starts with sponsorship and bringing women to the table in academic leadership positions so that our voices can be heard,” says Bridget Lang Findlay, MD.

"I am prepared and excited to be fully immersed in the health policy work of the AUA as the 2023 Gallagher Scholar," says Denise Asafu-Adjei, MD, MPH.

The clinical research program seeks to increase the number of URiM medical students entering the field of urology.